# Leigh Ryan

General Manager – Exploration

## Career chronology

- **Current at evidence cutoff: Horizon Gold Limited** — General Manager – Exploration. [Appointment of new CEO and MD](<https://www.intelligentinvestor.com.au/investment-tools/shares/asx-price-sensitive-announcements/asx-hrn/2482589>) (30 January 2026 CEO appointment announcement summary.)

## Personal achievements

### Relevant professional background and qualifications [hrn_leigh_ryan_background]

Previous career / current appointment; exact periods only where stated · issuer reported · medium materiality

Appointed MD in 2020; moved to General Manager – Exploration effective 2 February 2026.

**Attribution:** Individual involvement documented. This is an issuer-published career summary; it is not independent verification of every claimed contribution.

**Relevance:** The disclosed roles and qualifications bear on the executive’s general manager – exploration responsibilities.

[Appointment of new CEO and MD](<https://www.intelligentinvestor.com.au/investment-tools/shares/asx-price-sensitive-announcements/asx-hrn/2482589>) (announcement summary)

## Governance and interests

### Company disclosed a late director-interest filing [hrn_leigh_ryan_disclosure_oversight]

Director-interest notice due after 14 December 2023; disclosed 19 July 2024 · documented · low materiality

In July 2024 Horizon said it had overlooked filing an Appendix 3Y notice for options that expired on 14 December 2023 while Leigh Ryan was Managing Director. The issuer described the breach as a one-off administrative oversight, minor in nature, and not indicative of a systematic governance deficiency; it said improved notification systems were implemented.

**Attribution:** Role overlaps event; causation unproven. Ryan’s MD tenure overlapped the company-level filing control failure, but the issuer did not attribute personal responsibility to him. No inference of personal misconduct is made.

**Relevance:** The event bears on disclosure controls under executive oversight but is limited by its disclosed minor, one-off nature and remedial steps.

[Appendix 3Y – Change of Director’s Interest Notice](<https://company-announcements.afr.com/asx/hrn/2cdddc6b-4567-11ef-b51d-b681c1fa9655.pdf>) (p.1 lines 6–20)

## Suitability for the current role

### Current role relevance is supported at title level [hrn_leigh_ryan_role_fit]

At evidence cutoff · analyst inference · medium materiality

Analyst inference: the disclosed current title indicates experience relevant to the assigned function. The record reviewed does not establish individual delivery outcomes or independently verify credentials beyond the cited issuer disclosure.

**Attribution:** Responsibility not applicable. This is an analytical role-fit judgment, not a claim of proven performance.

**Relevance:** Current role scope is directly relevant to team composition; evidence of delivery remains limited.

[Appointment of new CEO and MD](<https://www.intelligentinvestor.com.au/investment-tools/shares/asx-price-sensitive-announcements/asx-hrn/2482589>) (30 January 2026 CEO appointment announcement summary.)

## Evidence gaps

- Independent verification of the complete career chronology, education and professional memberships is not established by the sources reviewed.

- No comprehensive regulator, court, safety, environment or litigation-record review was completed; absence of a finding here is not a clearance.

- Individual contribution to employer outcomes and concurrent board interests require additional source-level verification.
